Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlunestrant versus investigator's choice endocrine therapy, and imlunestrant plus abemaciclib, in ER-positive HER2-negative advanced or metastatic breast cancer
NL-OMON54215Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imlunestrant, abemaciclib, fulvestrant and exemestane in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival by investigator assessment. Started Sep 2022; status: recruiting.
02
Drugs
imlunestrantabemaciclibfulvestrantexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON54215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54215.